For April 2017, we have selected: Chen H, Kwong JC, Copes R, et al. Living near major roads and the incidence of dementia, Parkinson’s disease, and multiple sclerosis: a population-based cohort study. Lancet 2017:389;718-726.
Some studies have suggested that smog and noise can play a role in the pathogenesis of neurodegenerative disorders by inducing oxidative stress, neuroinflammation, microglia and neuronal antibody activation.
Category
Paper of the Month
-
-
Paper of the MonthFeatured Slider
Paper of the month: Migraine as a risk factor of perioperative ischemic stroke
March 1, 2017For March 2017, we have selected: Timm FP, Houle TT, Grabitz SD, et al. Migraine and risk of perioperative ischemic stroke and hospital readmission: hospital based registry study. BMJ 2017 Jan 10;356:i6635. doi: 10.1136/bmj.i6635. A higher risk of ischemic stroke has been found in patients with migraine, especially in those with migraine with aura. -
Paper of the MonthFeatured Slider
Paper of the month: Faster recovery after concussion with early participation to physical activities in pediatric patients
February 1, 2017For February 2017, we have selected: Grool AM, Aglipay M., Momoli F., et al., for the Pediatric Emergency Research Canada Concussion Team. Association between early participation in physical activity following acute concussion and persistent postconcussive symptoms in children and adolescents. JAMA 2017:316;2504-2514. Practical recommendations in the management of concussion in pediatric patients have stressed the need of physical and cognitive rest starting immediately after the injury. -
Paper of the MonthFeatured Slider
Paper of the month: Safer effective treatment for Ménière’s disease
January 3, 2017For January 2017, we have selected: Patel M, Agarwal K, Arshad Q, et al. Intratympanic methylprednisolone versus gentamicin in patients with unilateral Ménière’s disease: a randomized double-blind, comparative effectiveness trial. Lancet Neurol 2016;388:2753-2762. Disabling vertigo attacks and hearing loss are characteristics of Ménière’s disease. In patients with severe and frequent vertigo spells, intratympanic injections of gentamicin have proved to be effective, but at the price of permanent vestibular damage and hearing loss. -
Paper of the MonthTop ArticlesFeatured Slider
Paper of the month: Early diaphragm pacing should not be used in amyotrophic lateral sclerosis
December 1, 2016For December 2016 we have selected: Gonzales-Bermejo J, Morélot-Panzini C, Tanguy M-L, et al. Early diaphragm pacing in patients with amyotrophic lateral sclerosis (RespiStimALS): a randomized controlled triple-blind trial. Lancet Neurol 2016:15;1217-1227. The main cause of death in patients with amyotrophic lateral sclerosis (ALS) is related to respiratory failure. It has been hypothesized that diaphragm pacing (a technique that induces diaphragm contraction through the stimulation of the phrenic nerve) could slow the progression of respiratory muscle weakness, and increase alveolar ventilation and lung compliance in ALS patients. -
Paper of the MonthFeatured Slider
Paper of the month: Improved prognosis of multiple sclerosis in the last 10 years
November 1, 2016For November 2016 we have selected: Cree BAC, Gourraud P-A, Oksenberg JR, et al. Long-term evolution of multiple sclerosis disability in the treatment era. Ann Neurol 2016:80;499-510. Studies describing the natural history of multiple sclerosis (MS) before the availability of disease-modifying treatments have reported a progression of the disease from the relapsing-remitting form to the secondary progressive form in about 50% of patients at 19 years after the onset. -
Paper of the MonthFeatured Slider
Paper of the month and Scientific Debate: A new hope for Alzheimer’s disease treatment with the PRIME study?
October 1, 2016For October 2016 we have selected: Sevigny J, Chiao P, Bussiere T, et al. The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature 2016;537:50-56. Alzheimer’s disease (AD) is the most frequent neurodegenerative disorder. It is also extremely disabling with severe impact of the quality of life of patients and caregivers. The main pathological process is related to the toxic deposition of amyloid-β plaques and neurofibrillary tangles. No effective treatment is currently available to slow down the disease progression. -
Paper of the Month
Paper of the month: Percutaneous closure of patent foramen ovale does not reduce migraine duration
September 1, 2016For September 2016 we have selected: Mattle HP, Evers S, Hildick-Smith D, et al. Percutaneous closure of patent foramen ovale in migraine with aura, a randomized controlled trial. Eur Heart J 2016:37;2029-2036. There are about 50 million people suffering from migraine in Europe. About one third of the cases has migraine with aura, that has been found more prevalent in patients with patent foramen ovale (PFO). -
Paper of the MonthTop ArticlesFeatured Slider
Paper of the month: New genetic insights supporting the primary role of vascular dysfunction on migraine pathophysiology
August 1, 2016For August 2016 we have selected: Gormley P, Anttila V, Winsvold BS, et al. Meta-analysis of 375,000 individuals identifies 38 susceptibility loci for migraine. Nature Genetics 2016 June 20;doi: 10.1038/ng.3598. Migraine is a worldwide common, disabling, and costly disease. Its pathophysiology has been related to either a primary vascular dysfunction or a primary neuronal dysfunction with secondary vascular involvement. -
Paper of the MonthTop Articles
Paper of the month: Aspirin efficacy in secondary prevention of early ischaemic cerebrovascular events
July 1, 2016For July 2016 we have selected: Effects of aspirin on risk and severity of early recurrent stroke after transient ischaemic attack and ischaemic stroke: time-course analysis of randomized trials. Rothwell PM, Algra A, Chen Z, Diener H-C, Norrving B, Mehta Z. Lancet Neurol 2016 May 18. doi: 10.1016/S0140-6736(16)30468-8. Whereas there is robust evidence encouraging the use of aspirin for long-term secondary prevention after transient ischaemic attack (TIA) or ischaemic stroke, data supporting aspirin treatment to reduce early recurrence of ischæmic events is weak. Moreover, even less information is available concerning the early aspirin effects on risk or severity recurrence after minor strokes. -
Paper of the Month
Paper of the month: Botulinum toxin is effective for neuropathic pain
June 6, 2016For June 2016 we have selected: Safety and efficacy of repeated injections of botulinum toxin A in peripheral neuropathic pain (BOTNEP): a randomised, double-blind, placebo-controlled trial. Attal N, et al. Lancet Neurol 2016;15:555-565. The treatment of neuropathic pain is very challenging for neurologists and pain specialists since pain medications often have important adverse events or are partially effective. Botulinum toxin type A has been successfully used for many years to treat dystonia, spasticity, and other disorders with muscle hyperactivity. -
Paper of the Month
Paper of the month: Improved recovery from post-stroke aphasia with motor cortex electrical stimulation
May 4, 2016For May 2016 we have selected: Meinzer M, Darkow R, Lindenberg R, Flöel A. Electrical stimulation of the motor cortex enhances treatment outcome in post-stroke aphasia. Brain 2016:139;1152-1163. Language deficits after a stroke can be devastating and have a remarkable impact on the quality of life. Rehabilitation strategies can improve aphasia also in the chronic phases, but there is the overall need of more efficacious and focused treatment strategies. Transcranial direct current stimulation (tDCS) has been shown to change cortical excitability and induce synaptic plasticity without side effects. -
Paper of the MonthFeatured Slider
Paper of the month: Primary progressive multiple sclerosis still lacks effective treatment: no benefit from fingolimod.
April 1, 2016or April 2016 we have selected: Lublin F, Miller DH, Freedman MS, et al., on behalf of the INFORMS study investigators. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomized, double-blind, placebo-controlled trial. Lancet Neurol, 27 Jan 2016; pii: S0140-6736(15)01314-8. doi: 10.1016/S0140-6736(15)01314-8. Primary progressive multiple sclerosis (PPMS) represents around 10-15% of the clinical forms of MS. Several characteristics differentiate PPMS from the relapse-onset MS, the classical more frequent form: older age at onset, equal prevalence between sexes, less inflammatory component at the MRI, and quicker progression of disability. -
Paper of the Month
Paper of the month: Untreated cerebral cavernous malformations and risk of intracranial hemorrhage
March 1, 2016For March 2016 we have selected: Horne MA, Flemming KD, Su I-C, et al., and the Cerebral Cavernous Malformation Individual Patients Data Meta-analysis Collaborators. Clinical course of untreated cerebral cavernous malformations: a meta-analysis of individual patient data. Lancet Neurol 2016;15:166-173. The incidental finding of cerebral cavernous malformation (CCMs) in brain MRIs is relatively common (1/650 neurologically asymptomatic people, a prevalence second only to cerebral aneurysm). -
Paper of the Month
Paper of the month: Efficacy and safety of andexanet to reverse factor Xa inhibitors activity.
February 1, 2016For February 2016 we have selected: Siegal DM, Curnutte JT, Connolly SJ, et al. Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med 2015;33:2413-2424. There is an increased use of direct factor Xa inhibitors (like apixaban, rivaroxaban, and edoxaban) to prevent stroke in patients with nonvalvular atrial fibrillation since these medications have several advantages compared to vitamin K antagonists.